JP2009544721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544721A5 JP2009544721A5 JP2009521914A JP2009521914A JP2009544721A5 JP 2009544721 A5 JP2009544721 A5 JP 2009544721A5 JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009521914 A JP2009521914 A JP 2009521914A JP 2009544721 A5 JP2009544721 A5 JP 2009544721A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- phenyl
- pharmaceutically acceptable
- indol
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 18
- -1 2,6-dichloro-benzyl Chemical group 0.000 claims 16
- 229940002612 prodrug Drugs 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000000940 2-methoxyphenyl ethyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 229940124003 CRTH2 antagonist Drugs 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- LDXDSHIEDAPSSA-OAHLLOKOSA-N Ramatroban Chemical group N([C@@H]1CCC=2N(C3=CC=CC=C3C=2C1)CCC(=O)O)S(=O)(=O)C1=CC=C(F)C=C1 LDXDSHIEDAPSSA-OAHLLOKOSA-N 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 229940125388 beta agonist Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims 2
- 125000004441 haloalkylsulfonyl group Chemical group 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 229950004496 ramatroban Drugs 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 claims 1
- YZHLQIDOXFFHIC-UHFFFAOYSA-N 2-[2-[3-(cyclohexylsulfamoyl)-4-ethylphenyl]-1h-indol-3-yl]acetic acid Chemical compound CCC1=CC=C(C2=C(C3=CC=CC=C3N2)CC(O)=O)C=C1S(=O)(=O)NC1CCCCC1 YZHLQIDOXFFHIC-UHFFFAOYSA-N 0.000 claims 1
- CYEFWBZXGDCMEV-UHFFFAOYSA-N 2-[2-[4-chloro-3-(2-phenylethylsulfamoyl)phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCCC1=CC=CC=C1 CYEFWBZXGDCMEV-UHFFFAOYSA-N 0.000 claims 1
- MFZJSYNRDODMGM-UHFFFAOYSA-N 2-[2-[4-chloro-3-(3-phenylpropylsulfamoyl)phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCCCC1=CC=CC=C1 MFZJSYNRDODMGM-UHFFFAOYSA-N 0.000 claims 1
- SSWLGNBAUDIWAV-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]-n-(2h-tetrazol-5-yl)acetamide Chemical compound ClC1=CC=C(C2=C(C3=CC=CC=C3N2)CC(=O)NC=2NN=NN=2)C=C1S(=O)(=O)NC1CCCCC1 SSWLGNBAUDIWAV-UHFFFAOYSA-N 0.000 claims 1
- ZVYJBOYQGOAXMO-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]-n-(trifluoromethylsulfonyl)acetamide Chemical compound N1C2=CC=CC=C2C(CC(=O)NS(=O)(=O)C(F)(F)F)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 ZVYJBOYQGOAXMO-UHFFFAOYSA-N 0.000 claims 1
- YSASBPWWXZDHDU-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]-n-ethylsulfonylacetamide Chemical compound N1C2=CC=CC=C2C(CC(=O)NS(=O)(=O)CC)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 YSASBPWWXZDHDU-UHFFFAOYSA-N 0.000 claims 1
- PTZZCYIVRWCWRR-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]-n-methylacetamide Chemical compound N1C2=CC=CC=C2C(CC(=O)NC)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 PTZZCYIVRWCWRR-UHFFFAOYSA-N 0.000 claims 1
- YQKSEPAFDYUFEA-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]-n-methylsulfonylacetamide Chemical compound N1C2=CC=CC=C2C(CC(=O)NS(=O)(=O)C)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 YQKSEPAFDYUFEA-UHFFFAOYSA-N 0.000 claims 1
- ACORQNNZIIDWOY-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]propanoic acid Chemical compound N1C2=CC=CC=C2C(C(C(O)=O)C)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 ACORQNNZIIDWOY-UHFFFAOYSA-N 0.000 claims 1
- CBVVTYCQHBTMAE-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-4-fluoro-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC(F)=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 CBVVTYCQHBTMAE-UHFFFAOYSA-N 0.000 claims 1
- MYZYKAAKVDKIFT-UHFFFAOYSA-N 2-[2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-4-methyl-1h-indol-3-yl]acetic acid Chemical compound OC(=O)CC=1C=2C(C)=CC=CC=2NC=1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 MYZYKAAKVDKIFT-UHFFFAOYSA-N 0.000 claims 1
- OKWAHZPLRUETRX-UHFFFAOYSA-N 2-[2-[4-chloro-3-[(2,6-dichlorophenyl)methylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCC1=C(Cl)C=CC=C1Cl OKWAHZPLRUETRX-UHFFFAOYSA-N 0.000 claims 1
- HIVJYGKMPHTWPG-UHFFFAOYSA-N 2-[2-[4-chloro-3-[(3,5-dichlorophenyl)methylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCC1=CC(Cl)=CC(Cl)=C1 HIVJYGKMPHTWPG-UHFFFAOYSA-N 0.000 claims 1
- SPDHCHUIPQCJIT-UHFFFAOYSA-N 2-[2-[4-chloro-3-[(3-chlorophenyl)methylsulfonyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)CC1=CC=CC(Cl)=C1 SPDHCHUIPQCJIT-UHFFFAOYSA-N 0.000 claims 1
- GJWJWZDDQPPQAT-UHFFFAOYSA-N 2-[2-[4-chloro-3-[(3-chlorophenyl)methylsulfonylamino]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1NS(=O)(=O)CC1=CC=CC(Cl)=C1 GJWJWZDDQPPQAT-UHFFFAOYSA-N 0.000 claims 1
- LUOMPFDGGGWODV-UHFFFAOYSA-N 2-[2-[4-chloro-3-[2-(2,4-dichlorophenyl)ethylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCCC1=CC=C(Cl)C=C1Cl LUOMPFDGGGWODV-UHFFFAOYSA-N 0.000 claims 1
- NUCYUFBDBJIVJR-UHFFFAOYSA-N 2-[2-[4-chloro-3-[2-(2-methoxyphenyl)ethylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=CC=C1CCNS(=O)(=O)C1=CC(C2=C(C3=CC=CC=C3N2)CC(O)=O)=CC=C1Cl NUCYUFBDBJIVJR-UHFFFAOYSA-N 0.000 claims 1
- PQGJVVKDJSJIMD-UHFFFAOYSA-N 2-[2-[4-chloro-3-[2-(3-methoxyphenyl)ethylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound COC1=CC=CC(CCNS(=O)(=O)C=2C(=CC=C(C=2)C2=C(C3=CC=CC=C3N2)CC(O)=O)Cl)=C1 PQGJVVKDJSJIMD-UHFFFAOYSA-N 0.000 claims 1
- XEPDDBGYBLDMOH-UHFFFAOYSA-N 2-[2-[4-chloro-3-[2-(4-methoxyphenyl)ethylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCNS(=O)(=O)C1=CC(C2=C(C3=CC=CC=C3N2)CC(O)=O)=CC=C1Cl XEPDDBGYBLDMOH-UHFFFAOYSA-N 0.000 claims 1
- FXGKECGOCFYIRG-UHFFFAOYSA-N 2-[2-[4-chloro-3-[2-[2-(trifluoromethoxy)phenyl]ethylsulfamoyl]phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NCCC1=CC=CC=C1OC(F)(F)F FXGKECGOCFYIRG-UHFFFAOYSA-N 0.000 claims 1
- OAFWQOKONGHPNE-UHFFFAOYSA-N 2-[4-chloro-2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=CC=CC(Cl)=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 OAFWQOKONGHPNE-UHFFFAOYSA-N 0.000 claims 1
- VTPVWOAMVGZZKJ-UHFFFAOYSA-N 2-[7-chloro-2-[4-chloro-3-(cyclohexylsulfamoyl)phenyl]-1h-indol-3-yl]acetic acid Chemical compound N1C2=C(Cl)C=CC=C2C(CC(=O)O)=C1C(C=1)=CC=C(Cl)C=1S(=O)(=O)NC1CCCCC1 VTPVWOAMVGZZKJ-UHFFFAOYSA-N 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- UEAJFHLJMWRLBB-UHFFFAOYSA-N C(C)(=O)O.ClC1=C2C(=C(NC2=CC=C1)C1=CC(=C(C=C1)Cl)S(NC1CCCCC1)(=O)=O)[K] Chemical compound C(C)(=O)O.ClC1=C2C(=C(NC2=CC=C1)C1=CC(=C(C=C1)Cl)S(NC1CCCCC1)(=O)=O)[K] UEAJFHLJMWRLBB-UHFFFAOYSA-N 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 206010016946 Food allergy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical group CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
- JAUOIFJMECXRGI-UHFFFAOYSA-N Neoclaritin Chemical compound C=1C(Cl)=CC=C2C=1CCC1=CC=CN=C1C2=C1CCNCC1 JAUOIFJMECXRGI-UHFFFAOYSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- YEEZWCHGZNKEEK-UHFFFAOYSA-N Zafirlukast Chemical compound COC1=CC(C(=O)NS(=O)(=O)C=2C(=CC=CC=2)C)=CC=C1CC(C1=C2)=CN(C)C1=CC=C2NC(=O)OC1CCCC1 YEEZWCHGZNKEEK-UHFFFAOYSA-N 0.000 claims 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical group CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 230000020411 cell activation Effects 0.000 claims 1
- 229960001803 cetirizine Drugs 0.000 claims 1
- 229960001271 desloratadine Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229960003592 fexofenadine Drugs 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 229960003088 loratadine Drugs 0.000 claims 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960005127 montelukast Drugs 0.000 claims 1
- 208000008423 pleurisy Diseases 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical group FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims 1
- 229960002586 roflumilast Drugs 0.000 claims 1
- 229960002052 salbutamol Drugs 0.000 claims 1
- 238000006748 scratching Methods 0.000 claims 1
- 230000002393 scratching effect Effects 0.000 claims 1
- 208000037921 secondary disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 229960000195 terbutaline Drugs 0.000 claims 1
- 229960004764 zafirlukast Drugs 0.000 claims 1
- 0 CC1(*)C=CC(C(C(*)C(O)=O)=C(*2)c(cc3)cc(S(*C4CCCCC4)(=O)=O)c3*(I)=C)=C2C=C1 Chemical compound CC1(*)C=CC(C(C(*)C(O)=O)=C(*2)c(cc3)cc(S(*C4CCCCC4)(=O)=O)c3*(I)=C)=C2C=C1 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82029906P | 2006-07-25 | 2006-07-25 | |
| US82030106P | 2006-07-25 | 2006-07-25 | |
| US82030206P | 2006-07-25 | 2006-07-25 | |
| PCT/US2007/073945 WO2008014186A1 (en) | 2006-07-25 | 2007-07-20 | 2-phenyl-indoles as prostaglandin d2 receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544721A JP2009544721A (ja) | 2009-12-17 |
| JP2009544721A5 true JP2009544721A5 (enExample) | 2010-09-02 |
Family
ID=38610820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009521914A Abandoned JP2009544721A (ja) | 2006-07-25 | 2007-07-20 | プロスタグランジンｄ２受容体アンタゴニストとしての２−フェニルインドール類 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20090176804A1 (enExample) |
| EP (1) | EP2066628B1 (enExample) |
| JP (1) | JP2009544721A (enExample) |
| KR (1) | KR20090039735A (enExample) |
| AR (1) | AR062051A1 (enExample) |
| AT (1) | ATE485270T1 (enExample) |
| AU (1) | AU2007276885A1 (enExample) |
| BR (1) | BRPI0714554A2 (enExample) |
| CA (1) | CA2659055A1 (enExample) |
| CL (1) | CL2007002163A1 (enExample) |
| CO (1) | CO6190511A2 (enExample) |
| CR (1) | CR10577A (enExample) |
| DE (1) | DE602007010010D1 (enExample) |
| DK (1) | DK2066628T3 (enExample) |
| EC (1) | ECSP099087A (enExample) |
| GT (1) | GT200900016A (enExample) |
| IL (1) | IL196587A0 (enExample) |
| MA (1) | MA30643B1 (enExample) |
| MX (1) | MX2009000830A (enExample) |
| NO (1) | NO20090862L (enExample) |
| PE (1) | PE20080549A1 (enExample) |
| PT (1) | PT2066628E (enExample) |
| TN (1) | TNSN08515A1 (enExample) |
| TW (1) | TW200821286A (enExample) |
| WO (1) | WO2008014186A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2009072576A1 (ja) * | 2007-12-04 | 2011-04-28 | サッポロビール株式会社 | 骨形成促進剤 |
| PE20110703A1 (es) * | 2008-11-17 | 2011-10-13 | Hoffmann La Roche | Acidos naftilaceticos |
| PL2558447T3 (pl) | 2010-03-22 | 2015-03-31 | Idorsia Pharmaceuticals Ltd | Pochodne 3-(heteroaryloamino)-1,2,3,4-tetrahydro-9h-karbazolu i ich zastosowanie jako modulatorów receptora prostaglandyny D2 |
| US9096595B2 (en) | 2011-04-14 | 2015-08-04 | Actelion Pharmaceuticals Ltd | 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin D2 receptor modulators |
| EP3382391A1 (en) | 2012-10-24 | 2018-10-03 | NYU Winthrop Hospital | Non-invasive biomarker to identify subjects at risk of preterm delivery |
| JP2015089886A (ja) * | 2013-11-06 | 2015-05-11 | 国立大学法人名古屋大学 | 嵩高い置換基を有する化合物を用いた植物成長調整剤 |
| HUE039614T2 (hu) | 2014-03-17 | 2019-01-28 | Idorsia Pharmaceuticals Ltd | Azaindol-ecetsav-származékok és prosztaglandin D2 receptor modulátorokként történõ alkalmazásuk |
| KR20160133536A (ko) | 2014-03-18 | 2016-11-22 | 액테리온 파마슈티칼 리미티드 | 아자인돌 아세트산 유도체 및 프로스타글란딘 d2 수용체 조절제로서의 이의 용도 |
| MX379014B (es) | 2015-09-15 | 2025-03-10 | Idorsia Pharmaceuticals Ltd | Formas cristalinas. |
| KR20200109293A (ko) | 2017-09-13 | 2020-09-22 | 프로제너티, 인크. | 자간전증 바이오마커 및 관련된 시스템 및 방법 |
| WO2019166632A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| US12030879B2 (en) | 2018-03-02 | 2024-07-09 | Inflazome Limited | Sulfonyl acetamides as NLRP3 inhibitors |
| WO2019166627A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| WO2019166628A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| EP3759073A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Sulfonamide derivates as nlrp3 inhibitors |
| KR102863909B1 (ko) * | 2018-05-09 | 2025-09-23 | 글루콕스 바이오테크 에이비 | 선택적인 nox 저해 활성을 가진 새로운 설폰아미드 유도체 |
| EP4070113A4 (en) | 2019-12-04 | 2023-12-20 | Biora Therapeutics, Inc. | ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS |
| CN111333516B (zh) * | 2020-04-14 | 2022-09-06 | 国药集团化学试剂有限公司 | 一种2-氯-5-溴硝基苯的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DOP2006000016A (es) * | 2005-01-26 | 2006-07-31 | Aventis Pharma Inc | 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2. |
-
2007
- 2007-07-20 PT PT07799729T patent/PT2066628E/pt unknown
- 2007-07-20 AU AU2007276885A patent/AU2007276885A1/en not_active Abandoned
- 2007-07-20 WO PCT/US2007/073945 patent/WO2008014186A1/en not_active Ceased
- 2007-07-20 MX MX2009000830A patent/MX2009000830A/es active IP Right Grant
- 2007-07-20 AT AT07799729T patent/ATE485270T1/de active
- 2007-07-20 DE DE602007010010T patent/DE602007010010D1/de active Active
- 2007-07-20 DK DK07799729.4T patent/DK2066628T3/da active
- 2007-07-20 JP JP2009521914A patent/JP2009544721A/ja not_active Abandoned
- 2007-07-20 EP EP07799729A patent/EP2066628B1/en active Active
- 2007-07-20 BR BRPI0714554-3A patent/BRPI0714554A2/pt not_active IP Right Cessation
- 2007-07-20 CA CA002659055A patent/CA2659055A1/en not_active Abandoned
- 2007-07-20 KR KR1020097001687A patent/KR20090039735A/ko not_active Abandoned
- 2007-07-23 PE PE2007000951A patent/PE20080549A1/es not_active Application Discontinuation
- 2007-07-24 AR ARP070103291A patent/AR062051A1/es not_active Application Discontinuation
- 2007-07-24 CL CL200702163A patent/CL2007002163A1/es unknown
- 2007-07-25 TW TW096127005A patent/TW200821286A/zh unknown
-
2008
- 2008-12-12 TN TNP2008000515A patent/TNSN08515A1/en unknown
-
2009
- 2009-01-15 CO CO09002745A patent/CO6190511A2/es not_active Application Discontinuation
- 2009-01-19 IL IL196587A patent/IL196587A0/en unknown
- 2009-01-21 CR CR10577A patent/CR10577A/es not_active Application Discontinuation
- 2009-01-22 US US12/357,725 patent/US20090176804A1/en not_active Abandoned
- 2009-01-23 EC EC2009009087A patent/ECSP099087A/es unknown
- 2009-01-23 GT GT200900016A patent/GT200900016A/es unknown
- 2009-02-13 MA MA31635A patent/MA30643B1/fr unknown
- 2009-02-24 NO NO20090862A patent/NO20090862L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544721A5 (enExample) | ||
| JP2009533473A5 (enExample) | ||
| JP2008528606A5 (enExample) | ||
| ES2512727T3 (es) | Nuevos compuestos | |
| TWI429642B (zh) | 用於治療與醯基coA-二醯基甘油醯基轉移酶1活性有關聯之病症之化合物，包含其之醫藥組合物及其用途 | |
| RU2007132166A (ru) | 2-фенил-индолы как антагонисты рецепторов простагландина d2 | |
| JP2010523692A5 (enExample) | ||
| JP2010526777A5 (enExample) | ||
| JP2009523812A5 (enExample) | ||
| JP6008937B2 (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2013519680A5 (enExample) | ||
| JP2013542937A5 (enExample) | ||
| JP2004524301A5 (enExample) | ||
| JP2016535772A5 (enExample) | ||
| JPWO2011043359A1 (ja) | 芳香族複素環化合物を含有する医薬 | |
| US20090062294A1 (en) | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | |
| JP2008513515A5 (enExample) | ||
| JP2009539828A5 (enExample) | ||
| CN101932571A (zh) | 具有crth2拮抗活性的化合物 | |
| JP2009532372A5 (enExample) | ||
| JP2012255002A5 (enExample) | ||
| AR062051A1 (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d₂ | |
| JP2009504792A5 (enExample) | ||
| JP2015531774A5 (enExample) | ||
| JP2012501334A5 (enExample) |